已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

The efficacy and safety of efinaconazole 10% solution for treatment of mild to moderate onychomycosis: a pooled analysis of two phase 3 randomized trials.

医学 不利影响 临床试验 皮肤病科 子群分析 合并分析 治愈率 内科学 随机对照试验 人口 置信区间 环境卫生
作者
Aditya Gupta,Boni E. Elewski,Jeffrey L Sugarman,Chikara Ieda,Hideki Kawabata,Robert Kang,Radhakrishnan Pillai,Jason T. Olin,Shinichi Watanabe
出处
期刊:PubMed [National Institutes of Health]
卷期号:13 (7): 815-20 被引量:33
链接
标识
摘要

BACKGROUND: Onychomycosis is a fungal infection of the nail apparatus that can be challenging to treat due to the modest efficacy of existing antifungal therapies and a high rate of relapse and recurrence. OBJECTIVES: To investigate the efficacy and safety of efinaconazole 10% solution in pooled Phase III clinical trial participants with mild to moderate onychomycosis. METHODS: Phase III clinical trials data from NCT01008033 and NCT01007708 were pooled. Efficacy analysis for the primary and secondary outcome variables was conducted using the mITT population and analysed using Cochran-Mantel-Haenszel tests. Subgroup analysis was conducted for prognostic factors that may affect drug efficacy. Safety analysis was conducted on all recipients of a single drug dose. RESULTS: Efinaconazole 10% nail solution was superior to vehicle for all primary and secondary outcome measures assessed. Complete cure was 18.5% vs 4.7% P< 0.001 [mITT] and mycological cure was 56.3% vs 16.6%, P< 0.001 [mITT]. Complete or almost complete cure and treatment success were achieved in 27.7% and 47.2% compared to 7.9% and 18.2% with vehicle, respectively (P< 0.001 [mITT]). In all subgroups, efinaconazole 10% solution had statistically higher cures rates compared to vehicle. Higher complete cure rates were observed in women and individuals with mild disease (≤33% involvement), but not in any other subgroup assessed. Treatment associated adverse events in the efinaconazole 10% solution group were similar to vehicle and limited to local site reactions (2%). CONCLUSIONS: The findings from this pooled analysis suggest that efinaconazole 10% solution may become the preferred topical agent for mild to moderate onychomycosis.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
可爱的函函的应助被冷静白山采纳,获得10
1秒前
小六子完成签到,获得积分10
2秒前
lyy完成签到 ,获得积分10
2秒前
2秒前
桐桐的应助被南歪歪采纳,获得10
2秒前
3秒前
4秒前
桐桐的应助被yts8885采纳,获得10
5秒前
微山发布了新的文献求助10
5秒前
深情安青的应助被FF采纳,获得10
5秒前
该房地产个人的完成签到,获得积分0
6秒前
伊伊发布了新的文献求助10
6秒前
方好完成签到 ,获得积分10
6秒前
magical1991完成签到,获得积分10
7秒前
8秒前
9秒前
李明之发布了新的文献求助10
9秒前
10秒前
Jenny完成签到 ,获得积分10
11秒前
12秒前
magical1991发布了新的文献求助10
12秒前
12秒前
12秒前
12秒前
温暖砖头发布了新的文献求助10
13秒前
13秒前
hahahhah发布了新的文献求助10
13秒前
小二郎的应助被almost采纳,获得10
13秒前
小蘑菇的应助被zhang采纳,获得10
15秒前
DrZhu实验顺顺利利完成签到,获得积分10
15秒前
深情安青的应助被春风暮雪采纳,获得10
15秒前
15秒前
古德猫宁发布了新的文献求助10
17秒前
南歪歪发布了新的文献求助10
17秒前
Magic发布了新的文献求助10
19秒前
wxyaaa发布了新的文献求助10
19秒前
爆米花的应助被yts8885采纳,获得10
19秒前
jiewa发布了新的文献求助10
20秒前
哎健身发布了新的文献求助10
20秒前
21秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8184686
求助须知:如何正确求助?哪些是违规求助? 9573640
关于积分的说明 21832630
捐赠科研通 7782020
什么是DOI,文献DOI怎么找? 3434404
关于科研通互助平台的介绍 2558513
邀请新用户注册赠送积分活动 2481010